Product Name: DNAL1 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, ICC, IF, WB
Applications: DNAL1 antibody can be used for detection of DNAL1 by Western blot at 1 – 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 2.5 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: DNAL1 antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human DNAL1.The immunogen is located within the last 50 amino acids of DNAL1.
Host Species: Rabbit
Purification: DNAL1 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 474-25-9
Product: Chenodeoxycholic Acid
Buffer: DNAL1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: DNAL1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: DNAL1 Antibody: CILD16, C14orf168, Dynein light chain 1, axonemal
Accession NO.: NP_113615
Protein Ino: 164607156
Official Symbol: DNAL1
Geneid: 83544
Background: DNAL1 Antibody: DNAL1 was identified as a potential candidate gene for primary ciliary dyskinesia (PCD), a genetically heterologous disorder characterized by chronic infections of the upper and lower airways that often leads to permanent lung damage, randomization of left/right body symmetry, and reduced fertility. DNAL1 is reported to be expressed solely in tissues carrying motile cilia for flagella and interacts with DNAH5, a protein that when mutated has been shown to result in PCD. It has been suggested that DNAL1 serves a regulatory function for DNAH5 activity in outer dynein arms of sperm flagella, respiratory cilia, and ependymal cilia. DNAL1 has also been recently identified as an HIV dependency factor (HDF), suggesting that DNAL1 may be an important drug target in HIV treatment. At least two isoforms of DNAL1 are known to exist.
PubMed ID:http://aac.asm.org/content/38/10/2409.abstract
